An extension study to evaluate the sustainability of clinical benefits, safety and tolerability of secukinumab in patients with active Ankylosing Spondylitis (CAIN457F2305E1)
Phase 3
Completed
- Conditions
- ankylosing spondylitis10023213
- Registration Number
- NL-OMON44667
- Lead Sponsor
- ovartis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 9
Inclusion Criteria
• Subjects must have completed the core study
• Subjects who are deemed by the investigator to benefit from continued secukinumab therapy
Exclusion Criteria
• Any subject taking other concomitant biologic immunomodulating agent(s) except secukinumab during the core study
• Pregnancy, lactation.
• Women of childbearing potential who do not use adequate contraception.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>ASAS20.</p><br>
- Secondary Outcome Measures
Name Time Method <p>ASAS40, adverse events.</p><br>